Eupraxia Pharmaceuticals Inc. (OTCMKTS:EPRXF – Get Free Report) shares traded up 0.3% on Monday . The company traded as high as C$7.68 and last traded at C$7.57. 144,413 shares traded hands during mid-day trading, an increase of 1,849% from the average session volume of 7,410 shares. The stock had previously closed at C$7.55.
Eupraxia Pharmaceuticals Stock Performance
The company’s 50 day moving average price is C$6.33 and its 200-day moving average price is C$5.74.
Eupraxia Pharmaceuticals Company Profile
Eupraxia Pharmaceuticals, Inc (OTCMKTS:EPRXF) is a clinical-stage biotechnology company advancing adeno-associated virus (AAV)-based gene therapies for rare inherited metabolic disorders. The firm’s research platform focuses on developing single-administration treatments designed to address the underlying genetic causes of enzyme deficiencies. Eupraxia’s approach leverages targeted gene delivery to restore or supplement critical metabolic functions in patients with life-threatening conditions.
The company’s lead pipeline candidates include EPRX-101 for Ornithine Transcarbamylase (OTC) deficiency and EPRX-102 for methylmalonic acidemia (MMA), both of which are in preclinical or IND-enabling stages.
See Also
- Five stocks we like better than Eupraxia Pharmaceuticals
- A month before the crash
- How a Family Trust May Be Able To Help Preserve Your Wealth
- BNZI: BNZI Surges Ahead as AI Marketing Fuels Record Revenue
- A U.S. “birthright” claim worth trillions – activated quietly
- A Message From An Ex-CIA Officer About Trump
Receive News & Ratings for Eupraxia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eupraxia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
